Archive · 19 Dec 2025
Vijay Kedia Invests in SME Stock
Vijay Kedia, a well-known investor in India, has bought a big chunk of shares in a smaller company called Mahamaya Lifesciences.
This company makes products to protect crops and sells them to big companies and farmers.
Kedia's investment is a sign that he believes in the company's future.
The company has shown good growth in sales and profits, and it makes more money compared to its peers.
However, there are some risks, like the company's reliance on a few big customers and negative cash flow.
Kedia's investment has caused the company's stock price to go up a lot since it started trading.
Only time will tell if this investment will be successful.
Vijay Kedia's firm, Kedia Securities Pvt Ltd, purchased a 3.81% stake in Mahamaya Lifesciences Ltd, an SME agrochemical company, at an average price of Rs 140 per share.
Mahamaya Lifesciences has shown significant growth in sales (43% CAGR over the last 3 years), EBITDA (57% CAGR), and net profits (148% growth in FY25).
The company has high ROCE (26%) and ROE (35%), indicating efficient use of capital and equity.
Despite the growth, there are risks such as negative cash flow from operating activities (Rs 22.7 cr in FY24) and concentration risk, with the top 10 clients contributing 70% of revenue.
The stock price has surged by 61% since its IPO listing price of Rs 116, reaching Rs 187 as of 18th December 2025.
- Who
- Vijay Kedia, a prominent Indian investor, through his firm Kedia Securities Pvt Ltd
- What
- Purchased a 3.81% stake in Mahamaya Lifesciences Ltd, an SME agrochemical company
- When
- The deal was executed recently, with the stock price at Rs 140 per share
- Where
- The company is listed on the BSE’s SME Exchange
- Why
- Kedia sees potential in the company's growth, financial performance, and market potential, aligning with his 'SMILE' investment criteria
- Investor
- Vijay Kedia
- Company
- Mahamaya Lifesciences Ltd
- Shares Purchased
- 9 lakh
- Stake Purchased
- 3.81%
- Deal Value
- Rs 12.48 cr
- Average Price per Share
- Rs 140
- Company Market Cap
- Rs 432 cr
- Company IPO Price
- Rs 114
- Current Stock Price
- Rs 187 (as of 18th December 2025)
- Sales Growth (Last 3 Years)
- 43%
- EBITDA Growth (Last 3 Years)
- 57%
- Net Profit Growth (FY25)
- 148%
- ROCE
- 26%
- ROE
- 35%
- Debt-to-Equity Ratio
- 1.18
- PE Ratio
- 31x
- Industry Median PE Ratio
- 28x
- Negative Cash Flow (FY24)
- Rs 22.7 cr
- Top 10 Clients Contribution
- 70% of revenue